首页> 美国卫生研究院文献>Haematologica >Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug

【2h】

Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug

机译：慢性淋巴细胞性白血病T细胞和来那度胺作为免疫调节药物的免疫功能障碍

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

A new agent that is being used in chronic lymphocytic leukemia (CLL) and is receiving considerable interest is the immunomodulatory drug lenalidomide. The precise anti-CLL mechanism of action of lenalidomide is not yet completely defined. In this perspective article, Drs. Ramsay and Gribben examine the multiple biological effects of lenalidomide on various cell targets that likely contribute to its anti-CLL activity. See related paper on page 1266.

机译：免疫调节药物来那度胺是一种用于慢性淋巴细胞性白血病（CLL）并引起广泛关注的新药物。来那度胺的确切抗CLL作用机理尚未完全确定。在这篇观点文章中，Dr。 Ramsay和Gribben检查来那度胺对各种细胞靶标的多种生物学作用，这些靶标可能有助于其抗CLL活性。请参阅第1266页的相关论文。

著录项

期刊名称 Haematologica
作者
Alan G. Ramsay; John G. Gribben;
展开▼
作者单位

展开▼
年(卷),期 2009(94),9
年度 2009
页码 1198–1202
总页数 5
原文格式 PDF
正文语种
中图分类血液学检验;
关键词

相似文献

外文文献
中文文献
专利

1. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug | Haematologica [J] . Alan G. Ramsay, John G. Gribben Haematologica . 2009,第9期

机译：慢性淋巴细胞性白血病T细胞和来那度胺的免疫功能障碍作为免疫调节药物血液学
2. Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints [J] . Winqvist Maria, Mozaffari Fariba, Palma Marzia, Cancer immunology, immunotherapy : . 2017,第1期

机译：Lenalidomide和Alemtuzumab在难治性慢性淋巴细胞白血病（CLL）中的II-II研究：对T细胞和免疫检查点的影响
3. Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells [J] . Andrea Acebes-Huerta, Leticia Huergo-Zapico, Ana Pilar Gonzalez-Rodriguez, BioMed research international . 2014,第55期

机译：Lenalidomide诱导慢性淋巴细胞白血病免疫调节，增强NK和CD4 T细胞介导的抗肿瘤免疫应答
4. Detection of de novo IGHV mutations by ultra-deep sequencing from in vitro activated B-cell chronic lymphocytic leukemia cells: Evidence for activation-induced deaminase function [C] . Chu C.C., Patten P.E.M., MacCarthy T, International Congress of Immunology. . 2014

机译：通过来自体外活化B细胞慢性淋巴细胞白血病细胞超深序的De Novo IghV突变检测：活化诱导的脱氨酶功能的证据
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia [O] . Sarah E. M. Herman, Rosa Lapalombella, Amber L. Gordon, -1

机译：磷脂酰肌醇3-激酶-δ在来那度胺对慢性淋巴细胞白血病的免疫调节作用中的作用
7. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug [O] . Ramsay, Alan G., Gribben, John G. 2009

机译：慢性淋巴细胞性白血病T细胞和来那度胺作为免疫调节药物的免疫功能障碍

Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug

摘要

著录项

相似文献

相关主题

期刊订阅